Aditxt, Inc. (ADTX)
NASDAQ: ADTX · IEX Real-Time Price · USD
2.430
+0.020 (0.83%)
May 2, 2024, 1:08 PM EDT - Market open
Aditxt Revenue
In the year 2023, Aditxt had annual revenue of $645.18K, a decrease of -30.90%. Revenue in the quarter ending December 31, 2023 was $81.30K, a -56.20% decrease year-over-year.
Revenue (ttm)
$645.18K
Revenue Growth
-30.90%
P/S Ratio
7.33
Revenue / Employee
$13,727
Employees
47
Market Cap
4.71M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 645.18K | -288.54K | -30.90% |
Dec 31, 2022 | 933.72K | 828.68K | 788.96% |
Dec 31, 2021 | 105.03K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Leafly Holdings | 42.25M |
SunLink Health Systems | 39.59M |
Acutus Medical | 7.16M |
China Pharma Holdings | 7.01M |
Petros Pharmaceuticals | 5.82M |
Lipella Pharmaceuticals | 449.62K |
Oragenics | 37.65K |
ADTX News
- 4 weeks ago - Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) - Business Wire
- 5 weeks ago - Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 - PRNewsWire
- 6 weeks ago - Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal - PRNewsWire
- 2 months ago - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy - PRNewsWire
- 3 months ago - Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 - PRNewsWire
- 3 months ago - Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications - Business Wire
- 4 months ago - Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million - Business Wire
- 4 months ago - Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - Business Wire